Denali Therapeutics (DNLI) Non Operating Income (2017 - 2023)

Denali Therapeutics (DNLI) has 7 years of Non Operating Income data on file, last reported at $13.1 million in Q4 2023.

• On a quarterly basis, Non Operating Income rose 97.13% year-over-year to $13.1 million in Q4 2023; TTM through Dec 2023 was $51.5 million, a 248.62% increase from a year earlier, with the FY2023 full-year figure at $51.5 million, up 248.62% from the prior year.
• Non Operating Income for Q4 2023 stood at $13.1 million, down from $14.4 million in the prior quarter.
• Over the last five years, Non Operating Income for DNLI reached as high as $14.4 million in Q3 2023 and fell as low as $1.0 million in Q3 2021.
• Historically, Non Operating Income has averaged $5.2 million across 5 years, with a median of $3.1 million in 2020.
• Across the five-year window, Non Operating Income tumbled 82.96% in 2020 and surged 763.38% in 2023, its largest moves.
• Year by year, Non Operating Income stood at $11.4 million in 2019, then plunged by 85.72% to $1.6 million in 2020, then slipped by 21.17% to $1.3 million in 2021, then soared by 418.29% to $6.7 million in 2022, then soared by 97.13% to $13.1 million in 2023.
• Per Business Quant data, the three most recent Non Operating Income figures were $13.1 million in Q4 2023, $14.4 million in Q3 2023, and $12.9 million in Q2 2023.